ClinicalTrials.gg
Active, not recruitingNCT00867464Updated Nov 18, 2026

Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls

An observational study in Anal Carcinoma, Cervical Carcinoma and Human Papillomavirus Infection, sponsored by National Cancer Institute (NCI). Active, not recruiting at 1 site in Costa Rica. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by National Cancer Institute (NCI) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
8,670
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Anus Neoplasms by National Cancer Institute (NCI) — none open to participants now, 5 under way, 2 of them phase 3. Anus Neoplasms · National Cancer Institute (NCI).

Started
2009
with 1 other
Observational
2 of 23
none open now
Registered
9th of 23
by date

Among the 23 studies in Anus Neoplasms by National Cancer Institute (NCI), this one is one of 2 that started in 2009, is one of 2 observational ones, and was the 9th registered.

Anus Neoplasms

298 studies on the registry are indexed under Anus Neoplasms; 75 are open to participants now.

Browse Anus Neoplasms studies →

Open to participants now

None of the 23 studies in Anus Neoplasms by National Cancer Institute (NCI) is open now. The open studies under Anus Neoplasms, anywhere →

Who these studies take

Of the 57 Anus Neoplasms studies recruiting now, 46 (81%) set no upper age limit and 7 (12%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 23 studies in Anus Neoplasms by National Cancer Institute (NCI) as a file.
02

Study summary

This research trial studies extended follow up of young women in Costa Rica who received vaccine for human papillomavirus types 16 and 18 and unvaccinated controls. Collecting information from young women in Costa Rica who have received vaccine for human papillomavirus types 16 and 18 and a new group of unvaccinated controls enrolled for the follow-up period, may help doctors learn more about the risks and benefits of prophylactic human papillomavirus vaccine.

Read the detailed description

PRIMARY OBJECTIVES:

I. To evaluate the 10-year global impact of human papillomavirus (HPV)-16/18 vaccination of young adult women.

II. To evaluate determinants of the immune response to HPV and the vaccine, and markers of long-term protection.

III. To evaluate the natural history of HPV and cervical disease in vaccinated and unvaccinated populations.

OUTLINE:

Participants undergo long term follow-up comprising risk factor questionnaire, pelvic examination for all sexually experienced women, and specimen collection at years 6, 8, and 10.

03

Conditions studied

  • Anal Carcinoma
  • Cervical Carcinoma
  • Human Papillomavirus Infection
  • Human Papillomavirus-Related Cervical Carcinoma
  • Oral Cavity Carcinoma
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Young women in Costa Rica who received vaccination against human papillomavirus types 16 and 18 and unvaccinated controls.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women who participated in the Costa Rica Vaccine Trial (CVT) and lived in the Guanacaste province and a few areas of Puntarenas closest to Guanacaste will be eligible for the long-term follow up LTFU study
  • Women who received the HPV-16/18 vaccine at the start of CVT will be invited for up to 6 years of additional follow-up, and women who were originally in the control arm of CVT and were offered the HPV-16/18 vaccine at crossover will be invited for an additional 2 years of follow-up
  • A subset of the control arm women who are in the crossover immunogenicity subcohort will be followed the full 6 years
  • Some women who received HPV vaccination and were not invited into the LTFU protocol (stopped attending their screening visits during CVT, discontinued their study participation during CVT or lived outside the study area) will be invited to participate in the LTFU protocol, particularly those who received an incomplete vaccination schedule
  • UNVACCINATED CONTROL GROUP:
  • Born in or between July 1978 and November 1987
  • Residents of Guanacaste Province and a few areas of Puntarenas closest to Guanacaste at some point during 2005
  • Able to speak/understand Spanish
  • Apparently mentally competent
  • Written obtained prior to enrollment

Exclusion criteria

Exclusion Criteria:

  • History of cervical cancer
  • History of hysterectomy
  • Any important medical condition or other criteria that the investigator considers that precludes enrollment
  • Vaccination with Gardasil or Cervarix will be an exclusionary criterion, but few women are expected to have received these vaccines at the time of enrollment; use of these vaccines after enrollment is not a criterion for study interruption but we plan to collect information on vaccination history so that the few women who report having been vaccinated with one of the HPV vaccines after enrollment can be evaluated separately at analysis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
8,670 participants (estimated)
Biospecimen retention
Samples with dna

Groups and cohorts

  • Observational (long term follow-up)

    Participants undergo long term follow-up comprising risk factor questionnaire, pelvic examination for all sexually experienced women, and specimen collection at years 6, 8, and 10.

    Other: Cytology Specimen Collection Procedure · Other: Laboratory Biomarker Analysis · Other: Long-term Follow-up · Other: Questionnaire Administration

Interventions

  • OtherCytology Specimen Collection Procedure

    Correlative studies

    Also known as: Cytologic Sampling

  • OtherLaboratory Biomarker Analysis

    Correlative studies

  • OtherLong-term Follow-up

    Undergo extended follow-up

    Also known as: long term follow-up (clinical study), long-term follow-up (research), LTFU

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Cumulative rate of cervical intraepithelial neoplasia 3 (CIN3)

    Both absolute rate differences and percent reduction in rates will be evaluated.

    Time frame: At 10 years

  2. Level of immune response markers as prediction of long-term success of HPV vaccine

    For efficiency, a nested case-control approach is envisioned to evaluate this question. We propose to compare women who become infected against a subset of those who do not (non-failures) with respect to immune response markers of interest.

    Time frame: Up to 10 years

  3. Increase in the rate of cervical lesions associated with other carcinogenic HPV types that the vaccine does not protect against from prevention of HPV-16/18 associated cervical lesions through vaccination

    The 10-year cumulative rate of incident CIN2+ associated with HPV types other than HPV-16/18 and closely related HPV types in the alpha-7/9 species for which evidence of vaccine cross-protection is demonstrated will be compared between vaccinated and unvaccinated women.

    Time frame: Up to 10 years

07

Study locations

1 site
08

References and documents

Publications

  • Shing JZ, Hu S, Herrero R, Hildesheim A, Porras C, Sampson JN, Schussler J, Schiller JT, Lowy DR, Sierra MS, Carvajal L, Kreimer AR; Costa Rica HPV Vaccine Trial Group. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial. Lancet Oncol. 2022 Jul;23(7):940-949. doi: 10.1016/S1470-2045(22)00291-1. Epub 2022 Jun 13. PubMed 35709811 ↗
  • Porras C, Tsang SH, Herrero R, Guillen D, Darragh TM, Stoler MH, Hildesheim A, Wagner S, Boland J, Lowy DR, Schiller JT, Schiffman M, Schussler J, Gail MH, Quint W, Ocampo R, Morales J, Rodriguez AC, Hu S, Sampson JN, Kreimer AR; Costa Rica Vaccine Trial Group. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial. Lancet Oncol. 2020 Dec;21(12):1643-1652. doi: 10.1016/S1470-2045(20)30524-6. PubMed 33271093 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2009 (actual). Primary completion is estimated for Dec 2026, 212 months after the start.

Of 36 observational studies under Anus Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 137. This study's planned 212 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2009
First posted
Mar 23, 2009
StartActual
Mar 30, 2009
Primary completionEst.
Dec 23, 2026
CompletionEst.
Dec 23, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00867464
Responsible party
Sponsor
First posted
Mar 23, 2009
Start date
Mar 30, 2009
Primary completion
Dec 23, 2026 (estimated)
Completion
Dec 23, 2026 (estimated)
Last update
Nov 18, 2026

Study contacts

Aimee Kreimer
principal investigator · National Cancer Institute (NCI)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion